|18th May 2018
Precision medicine is set to revolutionise the healthcare sector, promising vastly improved outcomes for patients. However, as treatments become more precise, pharma companies will need to create more targeted commercial strategies. Meanwhile, the clinical trial recruitment process will become more challenging and a new series of stakeholders will emerge. These are just some of the barriers.
That’s why have dedicated the latest edition of our ‘Perspective’ magazine to this complex topic. We have combined the views of our in-house precision medicine experts and voices from key industry leaders to give you the latest information on the trend set to redefine healthcare as we know it – precision medicine.
In this edition of ‘Perspective’, we answer the following questions:
|16th August 2019
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to make a more accurate treatment decision. Here we discuss the barriers, opportunities and potential outcomes of the precision medicine era in healthcare.
|26th July 2019
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist and Director of Public Health at Genomics England, to find out how the NHS is achieving this goal.
|16th July 2019
The number of mental health research programmes in larger drug firms has shrunk by 70% in the past decade. Blue Latitude Health Senior Associate Consultant Sana Rahim explores this drop in investment and explains why developing a market-orientated model is vital for making progress.